292 related articles for article (PubMed ID: 15001357)
1. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
2. Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1.
Burch LR; Scott M; Pohler E; Meek D; Hupp T
J Mol Biol; 2004 Mar; 337(1):115-28. PubMed ID: 15001356
[TBL] [Abstract][Full Text] [Related]
3. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
4. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
[TBL] [Abstract][Full Text] [Related]
5. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization.
Peng Y; Chen L; Li C; Lu W; Chen J
J Biol Chem; 2001 Nov; 276(44):40583-90. PubMed ID: 11507088
[TBL] [Abstract][Full Text] [Related]
7. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.
Schon O; Friedler A; Freund S; Fersht AR
J Mol Biol; 2004 Feb; 336(1):197-202. PubMed ID: 14741215
[TBL] [Abstract][Full Text] [Related]
8. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel mdm2 binding peptides by phage display.
Böttger V; Böttger A; Howard SF; Picksley SM; Chène P; Garcia-Echeverria C; Hochkeppel HK; Lane DP
Oncogene; 1996 Nov; 13(10):2141-7. PubMed ID: 8950981
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
11. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
13. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p53 degradation by Mdm2 acetylation.
Wang X; Taplick J; Geva N; Oren M
FEBS Lett; 2004 Mar; 561(1-3):195-201. PubMed ID: 15013777
[TBL] [Abstract][Full Text] [Related]
15. The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.
Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
Biochem J; 2004 Aug; 381(Pt 3):685-91. PubMed ID: 15154850
[TBL] [Abstract][Full Text] [Related]
16. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
17. Chaperone-dependent stabilization and degradation of p53 mutants.
Muller P; Hrstka R; Coomber D; Lane DP; Vojtesek B
Oncogene; 2008 May; 27(24):3371-83. PubMed ID: 18223694
[TBL] [Abstract][Full Text] [Related]
18. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
[TBL] [Abstract][Full Text] [Related]
19. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
Fang S; Jensen JP; Ludwig RL; Vousden KH; Weissman AM
J Biol Chem; 2000 Mar; 275(12):8945-51. PubMed ID: 10722742
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]